GE HealthCare (GEHC) Q1 2026 earnings review
Solid Demand Overshadowed by Inflation and Margin Compression
GE HealthCare delivered healthy topline results in Q1, with revenue growing 7.4% YoY (2.9% organic) driven by strong demand in Pharmaceutical Diagnostics and Advanced Visualization. However, this growth failed to translate to the bottom line. Net Income plummeted 31% YoY as margins faced severe pressure from sudden inflation in memory chips, oil, and freight, alongside tariffs and a discrete PDx supplier issue. In response, management cut full-year profit and free cash flow guidance. The underlying demand remains stable, as evidenced by a record $21.8B backlog, but cost control and supply chain execution are now the primary concerns for investors.
🐂 Bull Case
The topline continues to accelerate. Total orders grew 1.1% organically on top of a tough double-digit comp from last year, pushing the backlog to $21.8 billion with a healthy book-to-bill ratio of 1.07x.
Pharmaceutical Diagnostics saw incredible 21.7% reported growth fueled by Flyrcado and contrast media. Advanced Visualization Solutions also shone with 8.2% growth and expanding margins.
🐻 Bear Case
Slashing profit and cash flow guidance in Q1 sets a negative tone. The cited 'pronounced inflation' in memory chips and freight appears sudden and raises questions about pricing power.
Patient Care Solutions (PCS) EBIT dropped 80% with margins falling to a dismal 1.4%. PDx margins also contracted by 680 bps due to a supplier issue, negating the segment's impressive volume growth.
⚖️ Verdict: 🔴
Bearish. While revenue growth is accelerating, the sudden compression in margins and the resulting cut to FY26 earnings and cash flow guidance early in the year indicate a reversing profitability trend that outweighs the solid demand.
Key Themes
Pronounced Inflation Sparks Guidance Cut
A major new headwind emerged in Q1: significant cost increases in memory chips, oil, and freight. This sudden inflation, coupled with ongoing tariffs, forced management to reduce their FY26 Adjusted EPS guidance from $4.95-$5.15 down to $4.80-$5.00. While they expect to offset 'more than half' of this impact via pricing and cost actions, the profitability trend is clearly decelerating.
Patient Care Solutions (PCS) Collapse
The PCS segment's performance is reversing dramatically. Revenue declined 6.5% YoY (down 8.1% organically), and EBIT collapsed by 79.8% to just $10 million. Segment EBIT margin plunged 500 bps YoY to an alarming 1.4%. This segment has been a persistent laggard and is now severely dragging down overall corporate margins.
PDx Margins Hit by Supplier Issue
Pharmaceutical Diagnostics (PDx) delivered accelerating revenue growth of 21.7% YoY, but this was completely disconnected from the bottom line. A 'discrete supplier issue' caused segment EBIT to fall 3.9%, driving a massive 680 bps contraction in EBIT margin (down to 25.6% from 32.4% in 25Q1). Management states the issue is resolved, but the lost profit in Q1 is unrecoverable.
Advanced Visualization Solutions (AVS) Outperformance
AVS was the clear bright spot, showing an accelerating trend in both revenue and profitability. Segment revenue grew 8.2% (4.4% organically), while EBIT surged 14.5% to $299 million. It was the only segment to expand its margin, up 120 bps to 22.3%, highlighting the value of GEHC's AI and software-enabled offerings.
Cloud-First Shift via Intelerad Acquisition
GEHC closed its $2.3 billion acquisition of Intelerad during the quarter. This is a significant strategic move designed to accelerate the company's shift toward cloud-enabled enterprise imaging across care settings. The financial contribution is baked into guidance as of mid-March, and it should bolster the software recurring revenue mix.
Innovation Pipeline Delivery
Management continues to execute on new product introductions. The quarter featured FDA clearances for the next-generation SIGNA MRI technology, View (a next-gen diagnostic viewer), and the Photonova Spectra photon-counting CT. Furthermore, the first patient was dosed in the Phase 2/3 LUMINA trial for a novel manganese-based MRI contrast agent.
Other KPIs
Remains highly stable. Total orders were up 1.1% organically (lapping a tough 10.3% comp in 25Q1), resulting in a healthy book-to-bill ratio of 1.07 times. This provides excellent revenue visibility despite the margin noise.
Up $13 million YoY. Despite the sharp drop in net income, operating cash flow improved to $290 million. The company continued to invest, increasing CapEx to $178 million (up from $152M), while also executing $100 million in share repurchases.
Guidance
Decelerating outlook. Reduced from previous guidance of $4.95-$5.15. While this still represents 4.6% to 9.0% YoY growth, the downward revision in Q1 due to inflation implies weaker operating leverage for the remainder of the year.
Decelerating outlook. Reduced from the previous expectation of 15.8%-16.1%. The new range implies a meager 10 to 40 bps expansion year-over-year, indicating that cost-cutting and pricing actions will only partially offset the new inflationary headwinds.
Stable. Unchanged from prior guidance. The 2.9% organic growth achieved in Q1 tracks perfectly with this full-year expectation, supported by the strong backlog.
Decelerating outlook. Trimmed from the prior estimate of approximately $1.7 billion, moving strictly in line with the reduced profit outlook.
Key Questions
Details on PDx Supplier Issue
You noted the discrete supplier issue in PDx has been resolved. What exactly was the nature of this disruption, and can you quantify the exact EBIT impact it had in Q1 to help us model the underlying run-rate for Q2?
Pricing Power Against Sudden Inflation
The inflation in memory chips, oil, and freight seems to have caught the company off guard, leading to a guidance cut. How much of a lag exists between these input cost spikes and your ability to pass them through via pricing on new contracts?
Path to Profitability in PCS
Patient Care Solutions margins have collapsed to 1.4%. Is this segment suffering from structural market issues or internal execution challenges? What is the specific timeline and strategy to return PCS to an acceptable margin profile?